Xeris Biopharma Holdings, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

XERS$15.20+16.2%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

Condensed Consolidated Balance Sheets

(in thousands, except share and par value)

	September 30, 2026	December 31, 2025
Assets · (unaudited)
Current assets:
Cash and cash equivalents	$131,082	$111,042
Trade accounts receivable, net	68,596	51,050
Inventory, net	76,925	68,673
Prepaid expenses and other current assets	12,662	9,548
Total current assets	289,265	240,313
Property and equipment, net	4,638	4,945
Operating lease right-of-use assets	21,584	22,112
Goodwill	22,859	22,859
Intangible assets, net	79,946	88,078
Other assets	4,927	5,220
Total assets	$423,219	$383,527
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$8,040	$3,076
Current operating lease liabilities	6,349	6,232
Other accrued liabilities	47,366	33,155
Accrued trade discounts and rebates	51,028	43,253
Accrued returns reserve	17,674	18,969
Other current liabilities	4,022	4,889
Total current liabilities	134,479	109,574
Long-term debt, net of unamortized debt issuance costs	189,713	220,335
Non-current operating lease liabilities	30,004	31,531
Other liabilities	20,239	8,398
Total liabilities	374,435	369,838
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of September 30, 2026 and December 31, 2025	—	—
Common stock—par value $0.0001, 350,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 182,567,511 and 166,215,410 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	19	17
Additional paid in capital	737,660	685,004
Accumulated deficit	(688,884)	(671,307)
Accumulated other comprehensive loss	(11)	(25)
Total stockholders' equity	48,784	13,689
Total liabilities and stockholders' equity	$423,219	$383,527

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data, unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Product revenue, net	$106,267	$74,063	$279,725	$199,573
Royalty, contract and other revenue	958	317	2,727	6,465
Total revenue	107,225	74,380	282,452	206,038
Costs and expenses:
Cost of goods sold	12,429	10,996	35,515	31,622
Research and development	11,058	7,483	30,510	23,291
Selling, general and administrative	64,108	46,459	178,287	134,870
Amortization of intangible assets	2,711	2,711	8,132	8,132
Total costs and expenses	90,306	67,649	252,444	197,915
Income from operations	16,919	6,731	30,008	8,123
Other income (expense):
Interest and other income	827	1,158	3,484	3,281
Loss on debt extinguishment, net	—	—	(30,782)	—
Interest expense	(6,456)	(7,268)	(20,287)	(21,931)
Total other expense	(5,629)	(6,110)	(47,585)	(18,650)
Net income (loss) before income taxes	11,290	621	(17,577)	(10,527)
Income tax benefit (expense)	—	—	—	—
Net income (loss)	$11,290	$621	$(17,577)	$(10,527)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(1)	(1)	14	—
Comprehensive income (loss)	$11,289	$620	$(17,563)	$(10,527)
Net income (loss) per common share - basic	$0.06	$0.00	$(0.10)	$(0.07)
Net income (loss) per common share - diluted	$0.06	$0.00	$(0.10)	$(0.07)
Weighted average common shares outstanding:
Basic	180,941,748	163,649,932	174,800,967	158,559,467
Diluted	189,924,032	177,617,307	174,800,967	158,559,467

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

(in thousands, except share data, unaudited)

Common Stock · Additional Paid InCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · TotalStockholders'Equity (Deficit)
Shares · Amount
Balance, December 31, 2024	149,429,410	$15	$642,256	$(25)		$(671,861)		$(29,615)
Net loss	—	—	—	—		(9,220)		(9,220)
Exercise of stock options	1,366,498	—	4,960	—		—		4,960
Vesting of restricted stock units (net of 2,255,124 shares withheld for tax)	3,721,805	1	(7,999)		—		(7,998)
Issuance of common shares in partial settlement of 2025 Convertible Debt	1,045,752	—	3,188	—		—		3,188
Issuance of common shares in settlement of warrants	450,585	—	—	—		—		—
Stock-based compensation	—	—	3,557	—		—		3,557
Balance, March 31, 2025	156,014,050	$16	$645,962	$(25)		$(681,081)		$(35,128)
Net loss	—	—	—	—		(1,928)		(1,928)
Exercise of stock options	315,724	—	1,152	—		—		1,152
Vesting of restricted stock units (net of 170,442 shares withheld for tax)	680,154	—	(859)	—		—		(859)
Issuance of common shares in settlement of 2025 Convertible Debt	3,932,399	—	11,958	—		—		11,958
Issuance of common stock through employee stock purchase plan	282,435	—	830	—		—		830
Stock-based compensation	—	—	4,670	—		—		4,670
Other comprehensive income	—	—	—	1		—		1
Balance, June 30, 2025	161,224,762	$16	$663,713	$(24)		$(683,009)		$(19,304)
Net income	—	—	—	—		621		621
Exercise of stock options	1,179,760	—	5,183	—		—		5,183
Vesting of restricted stock units (net of 93,725 shares withheld for tax)	167,986	—	(478)	—		—		(478)
Issuance of common shares for warrants exercised	2,955,745	1	9,166	—		—		9,167
Stock-based compensation	—	—	3,951	—		—		3,951
Other comprehensive loss	—	—	—	(1)		—		(1)
Balance, September 30, 2025	165,528,253	$17	$681,535	$(25)		$(682,388)		$(861)

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

(in thousands, except share data, unaudited)

Common Stock · Additional Paid InCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · TotalStockholders'Equity (Deficit)
Shares · Amount
Balance, December 31, 2025	166,215,410	$17	$685,004	$(25)	$(671,307)	$13,689
Net income	—	—	—	—	2,234	2,234
Exercise of stock options	259,935	—	847	—	—	847
Vesting of restricted stock units (net of 2,314,943 shares withheld for tax)	3,808,125	1	(17,018)	—	—	(17,017)
Issuance of common shares in settlement of warrants	2,275,313	—	7,333	—	—	7,333
Stock-based compensation	—	—	5,924	—	—	5,924
Other comprehensive income	—	—	—	1	—	1
Balance, March 31, 2026	172,558,783	$18	$682,090	$(24)	$(669,073)	$13,011
Net loss	—	—	—	—	(31,101)	(31,101)
Exercise of stock options	248,124	—	580	—	—	580
Vesting of restricted stock units (net of 31,690 shares withheld for tax)	363,980	—	(191)	—	—	(191)
Issuance of common stock through employee stock purchase plan	157,592	—	985	—	—	985
Issuance of common shares in settlement of warrants	263,158	—	600	—	—	600
Stock-based compensation	—	—	6,368	—	—	6,368
Other comprehensive income	—	—	—	14	—	14
Balance, June 30, 2026	173,591,637	$18	$690,432	$(10)	$(700,174)	$(9,734)
Net loss	—	—	—	—	11,290	11,290
Exercise of stock options	231,456	—	628	—	—	628
Vesting of restricted stock units (net of 93,156 shares withheld for tax)	141,245	—	(752)	—	—	(752)
Issuance of common shares in partial settlement of 2028 Convertible Debt	8,595,609	1	40,708	—	—	40,709
Issuance of common stock through employee stock purchase plan	7,564	—	47	—	—	47
Stock-based compensation	—	—	6,597	—	—	6,597
Other comprehensive income	—	—	—	(1)	—	(1)
Balance, September 30, 2026	182,567,511	$19	$737,660	$(11)	$(688,884)	$48,784

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.